Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Lymphedema is a chronic and progressive condition that causes swelling in the upper or lower limbs and affects millions of people. Currently, there are no effective drug treatments, and management mainly relies on compression therapy. This research aims to evaluate the potential benefits of glucagon-like peptide-1 receptor agonists GLP-1 RAs, which are commonly used for obesity and diabetes, for improving quality of life and clinical outcomes in lymphedema patients. The study addresses an important gap by providing prospective data on this treatment approach. Participants will receive GLP-1 RA treatment prescribed by their primary care provider for six months to assess its effects on lymphedema. The study is designed as a prospective, single-arm trial involving adults with unilateral upper or lower extremity lymphedema. Follow-up visits will occur at baseline, three months, and six months post-treatment to monitor progress. The study will collect data on limb volume, bioimpedance, compression use, and incidence of cellulitis alongside quality of life measures. During the study, participants will complete the Lymphedema Life Impact Scale LLIS to report their quality of life. Researchers will also measure limb volume, bioimpedance, body mass index BMI, compression use, and record any episodes of cellulitis. Safety will be monitored throughout, and serious adverse events will be reported promptly. The total participation period is 24 months, including follow-up and data analysis, to evaluate the treatments impact comprehensively.
Actively Recruiting
Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating the combination of osimertinib and bevacizumab versus osimertinib alone as first-line treatment for patients with advanced non-small cell lung cancer NSCLC that has spread beyond the lungs stage IIIB-IV and involves mutations in the EGFR gene. This phase III trial aims to determine if adding bevacizumab, which stops blood vessel growth to tumors, can better control cancer progression and improve survival compared to osimertinib alone. The study also examines overall survival, response rates, central nervous system progression, and treatment toxicity. Participants are randomly assigned to one of two groups one receives oral osimertinib daily, and the other receives oral osimertinib daily plus bevacizumab intravenously every 21 days. Treatment cycles repeat every 21 days unless disease progression or unacceptable side effects occur. Throughout the study, patients undergo various imaging tests including echocardiography, multigated acquisition scans, computed tomography, and possibly magnetic resonance imaging. Blood and urine samples are also collected to study treatment effects and resistance mechanisms. After finishing treatment, participants are monitored every three months for up to 10 years to track disease progression and survival. The main outcome measured is progression-free survival, defined as the time from starting treatment until cancer worsens or death. Secondary outcomes include overall survival, response rates, central nervous system involvement, and treatment safety. Regular assessments and sample collections help researchers understand how the treatments work and their long-term effects.
Actively Recruiting
Researchers are evaluating CARTISTEM, a new treatment made from stem cells derived from donated umbilical cord blood combined with a gel, to determine if it is safer and more effective than a standard surgical procedure called debridement for people with knee cartilage damage and osteoarthritis. This Phase 3 trial aims to show if CARTISTEM can reduce knee pain and improve function better than debridement two years after treatment. The study also investigates whether CARTISTEM may slow osteoarthritis progression using MRI scans. Participants will be divided into two groups one will receive CARTISTEM combined with debridement surgery, where the stem cell gel is placed into the damaged knee area after bone stimulation. The other group will undergo debridement surgery alone, which removes damaged cartilage and smooths the knee tissue. CARTISTEM involves mixing stem cells and a gel before placing it in the knee during surgery. Both groups will be monitored over two years. During the study, participants will have assessments of knee pain using the Visual Analog Scale and knee function using the WOMAC index from enrollment through 24 months. MRI scans will measure cartilage repair and osteoarthritis progression. Participants must follow rehabilitation requirements and limit other knee treatments during the trial. The study includes randomization and double-blinding to compare outcomes fairly while monitoring safety and effectiveness over time.
Actively Recruiting
This research aims to evaluate an experimental drug called REGN7508 in adults undergoing elective unilateral total knee replacement surgery. The study focuses on how well REGN7508 prevents venous thromboembolism VTE and related conditions after surgery. It also investigates side effects, blood levels of the study drug, and whether the body develops antibodies against the drug, which could affect its action or cause side effects. Participants are randomly assigned to receive one of several treatments intravenous REGN7508, subcutaneous REGN7508 with intravenous placebo, oral apixaban with intravenous placebo, or subcutaneous enoxaparin with intravenous placebo. All treatments are given according to the study protocol. The primary evaluation period lasts through approximately 14 days after surgery. During the study, participants undergo monitoring for VTE events including deep vein thrombosis and pulmonary embolism, bleeding events, and adverse reactions up to about 90 days after surgery. Blood samples are taken to measure drug concentration and antibody formation. The main outcome measured is the incidence of VTE through day 12. Safety and drug activity are closely tracked throughout the study period.
Actively Recruiting
Researchers are evaluating the addition of pembrolizumab, a type of immunotherapy, to standard chemotherapy for patients with stage IIA, IIB, IIIA, or IIIB non-small cell lung cancer NSCLC that has been completely removed by surgery. This phase III trial aims to compare disease-free survival and overall survival between different treatment approaches, including chemotherapy alone and chemotherapy combined with pembrolizumab. The study also investigates side effects, drug discontinuation rates, quality of life, and specific biomarkers such as PD-L1 expression and tumor mutational burden. Participants are randomly assigned to one of two treatment groups. Both groups initially receive one of four chemotherapy regimens every 21 days for four cycles, chosen by their doctor. In one group, pembrolizumab is given after chemotherapy as an intravenous infusion every 21 days for up to 17 cycles or every 6 weeks for up to 16 cycles. In the other group, pembrolizumab is given together with chemotherapy during the initial cycles and then continued as monotherapy. Patients undergo various scans and blood tests throughout the study, including echocardiograms, MRIs, CT scans, and blood sample collections. During the trial, participants are closely monitored for disease status and side effects. Follow-up visits occur six weeks after treatment, then every three months for two years, every six months for years two to four, and annually for up to ten years after randomization. Quality of life questionnaires and symptom assessments are also completed. The main measure of success is disease-free survival, tracked for up to five years after enrollment. Safety and overall survival are reviewed for up to ten years to ensure long-term monitoring.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the COMS One device in treating people with refractory diabetic foot ulcers DFUs. This prospective randomized, double-blinded, sham-controlled clinical trial aims to show that the COMS One device, used alongside standard care, can better promote wound closure compared to a sham device over 24 weeks. The main goal is to measure the time until complete wound healing, defined by full skin re-epithelialization without drainage. The study involves two groups one receiving the COMS One device and the other a sham device. Both devices include a reusable housing with controls and magnetic stimulation coils, a single-use sterile base called COMStouch, and a single-use strap called COMSfix to hold the device in place. Treatments are applied locally and participants continue standard wound care. The study plans to enroll 224 subjects after screening up to 450, with treatments lasting up to 24 weeks. Participants will attend regular visits to assess wound healing progress, safety, pain levels, and quality of life. Researchers will measure wound closure at multiple timepoints up to 24 weeks and monitor for adverse events, ulcer recurrence, and any need for amputation. The study includes careful monitoring of wound area reduction and participant-reported outcomes to evaluate the devices performance and safety throughout the trial.